Literature DB >> 23713868

Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.

Julia Alejandra Pezuk1, María Sol Brassesco, Andressa Gois Morales, Jaqueline Carvalho de Oliveira, Harley Francisco de Oliveira, Carlos Alberto Scrideli, Luiz Gonzaga Tone.   

Abstract

Despite efforts to improve surgical, radiologic, and chemotherapeutic strategies, the outcome of patients with glioblastoma (GBM) is still poor. Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays key roles in cell cycle control and has been associated with tumor growth and prognosis. Here, we aimed at testing the radiosensitizing effects of the PLK1 inhibitor BI 2536 on eight GBM cell lines. For cell cycle analysis, T98G, U251, U343 MG-a, LN319, SF188, U138 MG, and U87 MG cell lines were treated with 10, 50, or 100 nM of BI 2536 for 24 hours. In addition, cell cultures exposed to BI 2536 50 nM for 24 hours were irradiated with γ-rays from (60)Cobalt source at final doses of 2, 4, and 6 Gy. Combinatorial effects were evaluated through proliferation and clonogenic capacity assays. Treatment with BI 2536 caused mitotic arrest after 24 hours, and increased apoptosis in GBM cells. Moreover, our results demonstrate that pretreatment with this drug sensitized six out of seven GBM cell lines to different doses of γ-irradiation as shown by decreased growth and abrogation of colony-formation capacity. Our data suggest that PLK1 blockage has a radiosensitizing effect on GBM, which could improve treatment strategies for this devastating tumor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713868      PMCID: PMC3741430          DOI: 10.1089/cbr.2012.1415

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  43 in total

1.  A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.

Authors:  Nicholas Butowski; Michael D Prados; Kathleen R Lamborn; David A Larson; Patricia K Sneed; William M Wara; Mary Malec; Jane Rabbitt; Margaretta Page; Susan M Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

2.  Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.

Authors:  Kate Gerster; Wei Shi; Benjamin Ng; Shijun Yue; Emma Ito; John Waldron; Ralph Gilbert; Fei-Fei Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-01       Impact factor: 7.038

3.  Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

Authors:  Franz Rödel; Sarah Keppner; Gianni Capalbo; Robina Bashary; Manfred Kaufmann; Claus Rödel; Klaus Strebhardt; Birgit Spänkuch
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

4.  Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.

Authors:  Chao Zhang; Xiaodong Sun; Yuan Ren; Yunbo Lou; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

5.  In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines.

Authors:  Elisa Bordon; Leticia G Leon; Carla Rios-Luci; Pedro C Lara; Jose M Padron
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

6.  Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

Authors:  Nicholas Butowski; Susan M Chang; Kathleen R Lamborn; Mei-Yin Polley; Russell Pieper; Joseph F Costello; Scott Vandenberg; Rupa Parvataneni; Angelina Nicole; Patricia K Sneed; Jennifer Clarke; Emily Hsieh; Bruno M Costa; Rui M Reis; Maria Hristova-Kazmierski; Steven J Nicol; Donald E Thornton; Michael D Prados
Journal:  Neuro Oncol       Date:  2011-09-06       Impact factor: 12.300

7.  Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

Authors:  A Frost; K Mross; S Steinbild; S Hedbom; C Unger; R Kaiser; D Trommeshauser; G Munzert
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

Review 8.  Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.

Authors:  Jeffrey A Winkles; Gregory F Alberts
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

9.  Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.

Authors:  Eric F Johnson; Kent D Stewart; Keith W Woods; Vincent L Giranda; Yan Luo
Journal:  Biochemistry       Date:  2007-07-27       Impact factor: 3.162

Review 10.  Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.

Authors:  Patrick Schöffski
Journal:  Oncologist       Date:  2009-05-27
View more
  12 in total

1.  PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.

Authors:  Julia Alejandra Pezuk; María Sol Brassesco; Ricardo Santos de Oliveira; Hélio Rubens Machado; Luciano Neder; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2017-03-10       Impact factor: 1.475

2.  Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.

Authors:  Hui Shi; Shuo Sun; Haoyue Xu; Zongren Zhao; Zhengzhong Han; Jun Jia; Dongmei Wu; Jun Lu; Hongmei Liu; Rutong Yu
Journal:  Int J Nanomedicine       Date:  2020-05-12

3.  Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest.

Authors:  Jin-Yi Liu; Wei-Qi Fu; Xiang-Jin Zheng; Wan Li; Li-Wen Ren; Jin-Hua Wang; Cui Yang; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2020-05-25       Impact factor: 6.150

4.  Early Transcriptomic Response to LDL and oxLDL in Human Vascular Smooth Muscle Cells.

Authors:  Salvador Damián-Zamacona; Paola Toledo-Ibelles; Mabel Z Ibarra-Abundis; Laura Uribe-Figueroa; Enrique Hernández-Lemus; Karla Paola Macedo-Alcibia; Blanca Delgado-Coello; Jaime Mas-Oliva; Juan Pablo Reyes-Grajeda
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

5.  Effects of ionizing radiation on the viability and proliferative behavior of the human glioblastoma T98G cell line.

Authors:  Hossam Murad; Yaman Alghamian; Abdulmunim Aljapawe; Ammar Madania
Journal:  BMC Res Notes       Date:  2018-05-21

6.  Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.

Authors:  Alfiah Noor; Ijeoma Adaku Umelo; Peter Kronenberger; Philippe Giron; Elly De Vlieghere; Olivier De Wever; Erik Teugels; Jacques De Grève
Journal:  Oncotarget       Date:  2018-06-19

7.  Long noncoding RNA ENST00000413528 sponges microRNA-593-5p to modulate human glioma growth via polo-like kinase 1.

Authors:  Ren Zhang; Ruo-Lun Wei; Wei Du; Li-Wei Zhang; Tao Du; Ya-Dong Geng; Xin-Ting Wei
Journal:  CNS Neurosci Ther       Date:  2019-03-28       Impact factor: 5.243

8.  PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.

Authors:  Minoru Inoue; Michio Yoshimura; Minoru Kobayashi; Akiyo Morinibu; Satoshi Itasaka; Masahiro Hiraoka; Hiroshi Harada
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

9.  Network integration of multi-tumour omics data suggests novel targeting strategies.

Authors:  Ítalo Faria do Valle; Giulia Menichetti; Giorgia Simonetti; Samantha Bruno; Isabella Zironi; Danielle Fernandes Durso; José C M Mombach; Giovanni Martinelli; Gastone Castellani; Daniel Remondini
Journal:  Nat Commun       Date:  2018-10-30       Impact factor: 14.919

10.  Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.

Authors:  Jolien Van den Bossche; Andreas Domen; Marc Peeters; Christophe Deben; Ines De Pauw; Julie Jacobs; Sven De Bruycker; Pol Specenier; Patrick Pauwels; Jan Baptist Vermorken; Filip Lardon; An Wouters
Journal:  Cancers (Basel)       Date:  2019-11-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.